Scynexis Inc (SCYX) Stock Price, Quote & News

Company Profile

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automati...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 201 884 5485

Website: www.scynexis.com

Address:

1 Evertrust Plaza, 13th Floor, Jersey City, United States

DataJim Jul. 24 at 5:18 PM

$AMFN This week has been a bloodbath for me, but this has been the green light in the sea of red. It’s moved from 7th to 2nd without me adding. $SCYX is still my number one. This will have to double from here to pass it.

0 · Reply

sam2680 Jul. 23 at 6:41 PM

$SCYX

0 · Reply

goldwolf101 Jul. 23 at 2:19 PM

$SCYX To prison. ALL OF THEM !!!

0 · Reply

ViktorSinclair Jul. 21 at 4:33 PM

$SCYX making money is NOT managements objective. their goal is to continue doing their research as long as possible on other people’s dime. they never discuss shareholder value or even what their plan is to achieve earnings. it’s always about some potential technical achievement that never gets monetized. they ALL need to go.

0 · Reply

pantarei Jul. 21 at 5:47 AM

$SCYX rarely i have seen a so total disaster. Probably one of the worst managed company in the last ten years. They created more damage than benefit. Huge scam.

0 · Reply

DataJim Jul. 17 at 3:04 PM

$SCYX Why is this halted?

1 · Reply

pantarei Jul. 15 at 7:11 AM

$SCYX Where is Brexafemme? Where is GSK??

2 · Reply

BioRich Jul. 14 at 5:05 PM

$TLSA Looking great today. $SCYX recovering from the R/S daze nicely...should get legs soon. $NGEN, new to me, but I like what I see already. No idea on their cash position yet, but science is worth the look. $GUTS starting to get some attention. Keep them on your radar as we await their next data catalyst release. Side story with $GUTS is the expectation that they start their compliance run to a buck at any point. Institutions added and PTs getting raised is a great sign for a class-creating Cardio metabolic/Obesity sector play. $BIOA is another that's interesting and may get some renewed attention. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

2 · Reply

pantarei Jul. 14 at 2:56 PM

$SCYX what a sad view to see a quite dead company. No more hope, brexafemme out of the radar, no updates, no market credibility. Nothing, slowly bleeding till death :(

1 · Reply

DataJim Jul. 13 at 9:01 PM

$XBI $SCYX , $TLSA , $NGEN all green on a red day for xbi.

0 · Reply

Scynexis initiates SCY-770 study

Jun 30, 2026, 8:00 AM EDT - 25 days ago

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Jun 25, 2026, 9:30 AM EDT - 4 weeks ago

SCYNEXIS Transcript: AGM 2026

2026-05-29T23:51:41.000Z - 2 months ago

Scynexis trading halted, news pending

2026-05-22T20:21:28.000Z - 2 months ago

Scynexis announces 1-for-8 reverse stock split

May 22, 2026, 4:15 PM EDT - 2 months ago

SCYNEXIS Announces One-for-Eight Reverse Stock Split

May 19, 2026, 9:30 AM EDT - 2 months ago

SCYNEXIS Transcript: EGM 2026

2026-05-11T23:59:18.000Z - 2 months ago

Scynexis reports Q1 EPS (42c), consensus (12c)

May 11, 2026, 4:23 PM EDT - 2 months ago

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 11, 2026, 4:00 PM EDT - 2 months ago

SCYNEXIS Quarterly report: Q1 2026

May 11, 2026, 4:00 PM EDT - 2 months ago

SCYNEXIS Earnings release: Q1 2026

May 6, 2026, 9:15 PM EDT - 2 months ago

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

2026-05-01T20:05:19.000Z - 3 months ago

Scynexis files to sell 87M shares of common stock for holders

May 1, 2026, 8:00 AM EDT - 3 months ago

SCYNEXIS Registration statement: Registration filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

SCYNEXIS Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

SCYNEXIS Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 3 months ago

SCYNEXIS Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 3 months ago

SCYNEXIS Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 3 months ago

SCYNEXIS Proxy statement: Proxy filing

Mar 31, 2026, 8:30 AM EDT - 4 months ago

SCYNEXIS Transcript: M&A announcement

Mar 31, 2026, 8:30 AM EDT - 4 months ago

SCYNEXIS Press release: M&A announcement

Mar 31, 2026, 8:30 AM EDT - 4 months ago

SCYNEXIS Slides: M&A announcement

2026-03-31T11:20:57.000Z - 4 months ago

Poxel announces sale of PXL770 to Scynexis for up to $196M

Mar 31, 2026, 7:06 AM EDT - 4 months ago

Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million

2026-03-31T10:50:48.000Z - 4 months ago

Scynexis completes acquisition of PXL-770 for treatment of kidney disease

2026-03-31T10:50:10.000Z - 4 months ago

Scynexis announces $40M private placement

Mar 31, 2026, 6:45 AM EDT - 4 months ago

SCYNEXIS Announces $40.0 Million Private Placement

Mar 31, 2026, 6:40 AM EDT - 4 months ago

SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Mar 4, 2026, 4:20 PM EST - 5 months ago

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

Mar 4, 2026, 7:00 AM EST - 5 months ago

SCYNEXIS Earnings release: Q4 2025

Mar 4, 2026, 7:00 AM EST - 5 months ago

SCYNEXIS Annual report: Q4 2025

2026-02-26T13:32:37.000Z - 5 months ago

Scynexis announces first patients dosed in Phase 1 SAD, MAD trial of SCY-247

Feb 26, 2026, 8:23 AM EST - 5 months ago

SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247

2026-02-17T13:20:59.000Z - 5 months ago

Cero Therapeutics appoints Eric Francois to board of directors

Feb 17, 2026, 8:00 AM EST - 5 months ago

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

CRVO

2026-01-28T13:25:56.000Z - 6 months ago

Scynexis announces presentation highlighting data from SCY-247

2026-01-21T13:06:05.000Z - 6 months ago

Scynexis receives U.S. FDA QIDP, Fast Track Designations for SCY-247

2025-12-22T13:11:04.000Z - 7 months ago

Scynexis granted 180-day extension by Nasdaq to regain compliance

Dec 22, 2025, 8:00 AM EST - 7 months ago

SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

2025-11-19T12:11:19.000Z - 8 months ago

Scynexis completes transfer of BREXAFEMME NDA to GSK

GSK

Nov 19, 2025, 7:00 AM EST - 8 months ago

SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK

2025-11-17T15:20:08.000Z - 8 months ago

Scynexis announces grant for Hackensack Meridian, Johns Hopkins collaboration

2025-11-05T23:00:31.000Z - 9 months ago

Scynexis reports Q3 EPS (17c), consensus (20c)

Nov 5, 2025, 4:20 PM EST - 9 months ago

SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 5, 2025, 4:00 PM EST - 9 months ago

SCYNEXIS Earnings release: Q3 2025

Nov 5, 2025, 4:00 PM EST - 9 months ago

SCYNEXIS Quarterly report: Q3 2025

Nov 5, 2025, 7:00 AM EST - 9 months ago

SCYNEXIS Slides: investor presentation

2025-10-28T11:41:34.000Z - 9 months ago

Scynexis price target lowered to $3 from $4 at Guggenheim

GSK

2025-10-15T12:05:52.000Z - 10 months ago

Scynexis, GSK resolve disagreement related to restart of Phase 3 MARIO study

Oct 15, 2025, 8:00 AM EDT - 10 months ago

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study

2025-09-30T12:10:23.000Z - 10 months ago

Scynexis announces results from Phase 1 SAD/MAD study of SCY-247

Sep 4, 2025, 8:30 AM EDT - 11 months ago

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)

Aug 13, 2025, 4:30 PM EDT - 1 year ago

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 7:00 AM EDT - 1 year ago

SCYNEXIS Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

SCYNEXIS Quarterly report: Q2 2025

May 28, 2025, 8:30 AM EDT - 1 year ago

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

May 15, 2025, 4:00 PM EDT - 1 year ago

SCYNEXIS Earnings release: Q1 2025

May 15, 2025, 4:00 PM EDT - 1 year ago

SCYNEXIS Quarterly report: Q1 2025

Apr 30, 2025, 8:00 AM EDT - 1 year ago

SCYNEXIS Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

SCYNEXIS Proxy statement: Proxy Filing

Mar 12, 2025, 5:08 PM EDT - 1 year ago

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 12, 2025, 5:00 PM EDT - 1 year ago

SCYNEXIS Annual report: Q4 2024

Mar 12, 2025, 5:00 PM EDT - 1 year ago

SCYNEXIS Earnings release: Q4 2024

Nov 6, 2024, 4:30 PM EST - 1 year ago

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 18, 2024, 4:00 PM EDT - 1 year ago

SCYNEXIS Quarterly report: Q3 2024

Oct 10, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 3, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

Sep 11, 2024, 10:00 AM EDT - 2 years ago

SCYNEXIS Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 27, 2024, 8:00 AM EDT - 2 years ago

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 4:30 PM EDT - 2 years ago

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 8, 2024, 4:00 PM EDT - 2 years ago

SCYNEXIS Quarterly report: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

SCYNEXIS Earnings release: Q2 2024

Jul 23, 2024, 7:00 AM EDT - 2 years ago

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

May 8, 2024, 4:30 PM EDT - 2 years ago

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 4:00 PM EDT - 2 years ago

SCYNEXIS Quarterly report: Q1 2024

May 8, 2024, 4:00 PM EDT - 2 years ago

SCYNEXIS Earnings release: Q1 2024

Apr 30, 2024, 4:05 PM EDT - 2 years ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

Apr 25, 2024, 8:00 AM EDT - 2 years ago

SCYNEXIS Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

SCYNEXIS Proxy statement: Proxy Filing

Apr 9, 2024, 4:05 PM EDT - 2 years ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Mar 28, 2024, 4:01 PM EDT - 2 years ago

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 28, 2024, 4:00 PM EDT - 2 years ago

SCYNEXIS Earnings release: Q4 2023

Mar 28, 2024, 4:00 PM EDT - 2 years ago

SCYNEXIS Annual report: Q4 2023

Feb 7, 2024, 11:00 AM EST - 2 years ago

SCYNEXIS Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Jan 29, 2024, 5:15 PM EST - 2 years ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

Jan 5, 2024, 8:30 AM EST - 2 years ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

Dec 28, 2023, 9:00 AM EST - 2 years ago

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options

DataJim Jul. 24 at 5:18 PM

0 · Reply

sam2680 Jul. 23 at 6:41 PM

$SCYX

0 · Reply

goldwolf101 Jul. 23 at 2:19 PM

$SCYX To prison. ALL OF THEM !!!

0 · Reply

ViktorSinclair Jul. 21 at 4:33 PM

0 · Reply

pantarei Jul. 21 at 5:47 AM

$SCYX rarely i have seen a so total disaster. Probably one of the worst managed company in the last ten years. They created more damage than benefit. Huge scam.

0 · Reply

DataJim Jul. 17 at 3:04 PM

$SCYX Why is this halted?

1 · Reply

pantarei Jul. 15 at 7:11 AM

$SCYX Where is Brexafemme? Where is GSK??

2 · Reply

BioRich Jul. 14 at 5:05 PM

2 · Reply

pantarei Jul. 14 at 2:56 PM

$SCYX what a sad view to see a quite dead company. No more hope, brexafemme out of the radar, no updates, no market credibility. Nothing, slowly bleeding till death :(

1 · Reply

DataJim Jul. 13 at 9:01 PM

$XBI $SCYX , $TLSA , $NGEN all green on a red day for xbi.

0 · Reply

DataJim Jul. 12 at 1:08 AM

$SCYX @Rodzilla01 - i’m curious if this is on your radar. Getting this in the fours reminds me of $ZVRA at $4.45. They have an approved drug with two big Pharma partners. They are a leader in antifungal with a very promising pipeline. They have a promising kidney drug and a cash runway out to 2029.

2 · Reply

DataJim Jul. 9 at 7:53 PM

$SCYX Sold $AVDV to load up here. This is gonna 4X in the next couple of years.

0 · Reply

DataJim Jul. 8 at 10:38 PM

$SCYX https://chatgpt.com/share/6a4ed13e-8168-83e8-86c4-42425c171cce

1 · Reply

LemuelPitkin Jul. 8 at 9:45 PM

$SCYX AI: Brexafemme (ibrexafungerp) exhibits both fungistatic and fungicidal activity against Coccidioides. Pre-clinical studies and murine models indicate that while early treatment effects are primarily fungistatic, the drug converts to a fungicidal effect (causing fungal cell lysis) as drug concentrations accumulate over time.In development for refractory fungal diseases like coccidioidomycosis (Valley Fever), the drug targets β-(1,3)-D-glucan synthase.

0 · Reply

LemuelPitkin Jul. 8 at 9:35 PM

$SCYX Coccidioides was one of the targets for Brexafemme research that GSK paid millions to prevent going forward. Brexafemme preliminary: It is fungostatic to Coccidioides. https://www.dailymail.com/sciencetech/article-15962385/fungal-storms-valley-fever-america.html From Daily Mail: Giant storms filled with potentially deadly fungal spores are set to sweep across at least 11 US states this summer, with the worst conditions still weeks away. Meteorologists and health experts have warned that dust storms in the Southwest will stir up dangerous fungal spores from the soil through September, potentially exposing millions to Valley fever. This common illness is a lung infection caused by breathing in microscopic fungus particles called Coccidioides that live in dry soil frequently blown around by strong desert winds. The spores turn into growing fungal cells that the immune system typically fights off, causing mild flu-like symptoms such as fever, cough and headaches in most patients, but severe infections can spread to the organs and bones and become fatal.

0 · Reply

alexpitti Jul. 7 at 8:31 PM

i'm meeting with the ceos of $BHST $HELP $SCYX in the coming 2-3 weeks

3 · Reply

Zenlama Jul. 6 at 7:21 PM

$SCYX It's nice when it's quiet. I think this is gonna be a winner.

1 · Reply

TakeWhatYouGet Jul. 2 at 5:50 PM

$SCYX noice win and out

0 · Reply

BIG_BEAR_FINANCIAL_LLC Jul. 1 at 3:45 PM

$SLS long bull here and I’m convinced that GPS will meet its endpoints. However I’m a little worried, what happens after ? Let’s say there is no buyout ? After all AML CR2 has a TAM of just a few thousand patients a year, even with a very high cost I can’t see the market being larger than $300 million or so. Right now we are almost at $3 billion so that’s already 10x sales at most (more likely will be 50x sales to start). I can’t see any BP buying us out at this valuation ? Since Sterg doesn’t want to go it alone, but with no buyout, that leaves us to subcontracting the commercialization and marketing. I’ve seen many failed companies with approved once promising drugs fail this route, see $SCYX for instance.

6 · Reply

ViktorSinclair Jun. 30 at 4:27 PM

$SCYX when they acquired the rights to this they said this ALREADY COMPLETED a phase 1 and i think some additional studies as well . why are they doing phase 1 over? how come there was no mention of that within the PR? things like this make David look like a fool. He needs to TALK to the public and take questions.

0 · Reply

LemuelPitkin Jun. 30 at 2:06 PM

$SCYX I am relieved. This is a very short study and now it makes sense.

0 · Reply

Market Cap	39.32M
Revenue (ttm)	20.60M
Net Income (ttm)	-8.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-41.80%
Debt to Equity Ratio	0.00

Volume	91,000
Avg Vol	76,497
Day's Range	N/A - N/A
Shares Out	9.93M
Stochastic %K	4%
Beta	1.11
Analysts	Strong Sell
Price Target	$33.55